---
layout: post
title: "QTc Information in Human Prescription Drug and Biological Product Labeling; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:56:24 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-16930
original_published: 2023-08-08 00:00:00 +0000
significance: 8.00
---

# QTc Information in Human Prescription Drug and Biological Product Labeling; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 08, 2023 00:00 UTC
**Document Number:** 2023-16930

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "QTc Information in Human Prescription Drug and Biological Product Labeling." This guidance is intended to assist applicants with incorporating corrected QT (QTc) interval prolongation-related information into the labeling of non-antiarrhythmic human prescription drug and biological products. The guidance provides recommendations on how and where to appropriately include the clinically relevant information on QTc interval prolongation in the labeling, in accordance with regulatory requirements for the content and format of human prescription drug labeling.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/08/2023-16930/qtc-information-in-human-prescription-drug-and-biological-product-labeling-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-16930

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
